NR2F1-induced NR2F1-AS1 promotes esophageal squamous cell carcinoma progression via activating Hedgehog signaling pathway

2019 ◽  
Vol 519 (3) ◽  
pp. 497-504 ◽  
Author(s):  
Yaowen Zhang ◽  
Anping Zheng ◽  
Ruiping Xu ◽  
Fuyou Zhou ◽  
Anlin Hao ◽  
...  
2020 ◽  
Vol 319 (1) ◽  
pp. C93-C104
Author(s):  
Nuo Li ◽  
Yang Yu ◽  
Baoming Wang

Esophageal squamous cell carcinoma (ESCC) ranks among the five most common cancers in China and has a five-year survival rate of less than 15%. The transcription factor ATPase-family AAA-domain-containing protein 2 (ATAD2) has potential as a therapeutic target in various tumors, and microarray-based gene expression profiling reveals dysregulation of ATAD2 specifically in ESCC. Here we investigated whether ATAD2 could mediate a regulation of cancer stem cell (CSC) biological functions in ESCC. Immunohistochemical staining, reverse transcription quantitative polymerase chain reaction, and Western blot assays all revealed upregulation of ATAD2 in ESCC tissues and cell lines, which furthermore correlated with progression of ESCC. In loss-of-function experiments, silencing of ATAD2 inhibited activation of the Hedgehog signaling pathway, as indicated by reduced expression of glioma-associated oncogene family zinc finger 1 (Gli1), smoothened frizzled class receptor (SMO), and patched 1 (PTCH1). Investigations with 5-ethynyl-2′-deoxyuridine (EdU), Transwell assay, scratch test, flow cytometry, and colony formation assay showed that silencing of ATAD2 or inhibiting the Hedgehog signaling decreased the proliferation, invasion, and migration abilities along with colony formation, but elevated the apoptosis rate of CSCs. Furthermore, in vivo experiments validated the suppressive effect of siRNA-mediated ATAD2 silencing on tumor growth in nude mice. Thus, downregulation of ATAD2 can seemingly restrain the malignant phenotypes of ESCC cells through inhibition of the Hedgehog signaling pathway.


2018 ◽  
Vol 19 (9) ◽  
pp. 2485 ◽  
Author(s):  
Stephanie Hehlgans ◽  
Patrick Booms ◽  
Ömer Güllülü ◽  
Robert Sader ◽  
Claus Rödel ◽  
...  

Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation sensitizing effects of vismodegib by analyzing viability, cell cycle distribution, cell death, DNA damage repair and clonogenic survival in three-dimensional cultures of a BCC and a head and neck squamous cell carcinoma (HNSCC) cell line. We found that vismodegib decreases expression of the Hedgehog target genes glioma-associated oncogene homologue (GLI1) and the inhibitor of apoptosis protein (IAP) Survivin in a cell line- and irradiation-dependent manner, most pronounced in squamous cell carcinoma (SCC) cells. Furthermore, vismodegib significantly reduced proliferation in both cell lines, while additional irradiation only slightly further impacted on viability. Analyses of cell cycle distribution and cell death induction indicated a G1 arrest in BCC and a G2 arrest in HNSCC cells and an increased fraction of cells in SubG1 phase following combined treatment. Moreover, a significant rise in the number of phosphorylated histone-2AX/p53-binding protein 1 (γH2AX/53BP1) foci in vismodegib- and radiation-treated cells was associated with a significant radiosensitization of both cell lines. In summary, these findings indicate that inhibition of the Hedgehog signaling pathway may increase cellular radiation response in BCC and HNSCC cells.


RSC Advances ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 3256-3265 ◽  
Author(s):  
Xiaoqi Chen ◽  
Zhuan Lv ◽  
Chuanlei Zhang ◽  
Xinting Wang ◽  
Yunxia Zhao ◽  
...  

PNS regulate VEGF expression to suppress ESCC progression via the DVL3-mediated Wnt/β-catenin signaling pathway.


2020 ◽  
Vol 474 (1-2) ◽  
pp. 181-188 ◽  
Author(s):  
Yasaman Fahim ◽  
Mozhgan Yousefi ◽  
Mohammad Hossein Izadpanah ◽  
Mohammad Mahdi Forghanifard

2014 ◽  
Vol 289 (1-2) ◽  
pp. 91-96 ◽  
Author(s):  
Deyu Chen ◽  
Zhaoyue Zhang ◽  
Chaoming Mao ◽  
Yuepeng Zhou ◽  
Lichao Yu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document